Načítá se...
Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce the risk of tumour recurrence after liver transplantation for hepatocellular carcinoma (HCC). However, their role in established post-transplant HCC recurrence is uncertain. AIM: To investigate whether mTOR inhibit...
Uloženo v:
| Vydáno v: | World J Gastrointest Surg |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7215969/ https://ncbi.nlm.nih.gov/pubmed/32426094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4240/wjgs.v12.i4.149 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|